ABVC BioPharma (NASDAQ:ABVC) Posts Quarterly Earnings Results, Beats Estimates By $0.37 EPS

ABVC BioPharma (NASDAQ:ABVC) issued its earnings results on Wednesday. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.37, Zacks reports.

ABVC BioPharma Price Performance

ABVC traded down $0.02 during trading on Wednesday, reaching $0.96. 282,216 shares of the company’s stock were exchanged, compared to its average volume of 105,262. ABVC BioPharma has a 1 year low of $0.88 and a 1 year high of $3.40. The company’s fifty day simple moving average is $1.32 and its 200-day simple moving average is $1.35. The stock has a market capitalization of $25.49 million, a P/E ratio of -2.40 and a beta of 0.57.

Institutional Trading of ABVC BioPharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC raised its holdings in shares of ABVC BioPharma by 7.7% during the fourth quarter. Geode Capital Management LLC now owns 202,365 shares of the company’s stock worth $431,000 after purchasing an additional 14,553 shares during the last quarter. Millennium Management LLC purchased a new stake in ABVC BioPharma in the third quarter valued at $60,000. Finally, Citadel Advisors LLC purchased a new stake in ABVC BioPharma in the third quarter valued at $48,000. Institutional investors and hedge funds own 11.38% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded ABVC BioPharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, ABVC BioPharma presently has an average rating of “Sell”.

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.